The Effect of Jazar Supplement on Quality of Life and Sexual Function in Postmenopausal Women: A Double-Blind, Randomized, Placebo-Controlled Trial

Table 3

A summary of changes in the scores of the FSFI subscales during the trial period.

Subscales	Measurement points	Jazar (n = 43)	Placebo (n = 41)	value
Desire	Baseline	2.10 ± 1.31	1.56 ± 1.32	0.063
	Week 4	2.83 ± 0.85	2.04 ± 1.24	0.001
	Week 8	3.23 ± 0.74	2.22 ± 1.48	<0.001
	Week 10	3.12 ± 0.84	1.97 ± 1.56	<0.001
Arousal	Baseline	1.96 ± 1.35	1.40 ± 1.31	0.057
	Week 4	2.77 ± 1.07	1.91 ± 1.39	0.002
	Week 8	3.04 ± 0.95	1.90 ± 1.49	<0.001
	Week 10	2.95 ± 1.05	1.92 ± 1.49	<0.001
Lubrication	Baseline	2.25 ± 1.75	1.83 ± 1.68	0.607
	Week 4	3.43 ± 1.50	2.34 ± 1.63	0.002
	Week 8	3.60 ± 1.53	2.15 ± 1.77	<0.001
	Week 10	3.59 ± 1.55	2.13 ± 1.86	<0.001
Satisfaction	Baseline	2.43 ± 1.89	1.79 ± 1.69	0.270
	Week 4	3.55 ± 1.48	2.44 ± 1.76	0.002
	Week 8	3.86 ± 1.27	2.53 ± 1.81	<0.001
	Week 10	3.67 ± 1.57	2.44 ± 1.93	0.002
Orgasm	Baseline	2.91 ± 1.93	2.23 ± 1.73	0.106
	Week 4	4.05 ± 1.40	2.90 ± 1.80	0.002
	Week 8	4.25 ± 1.28	2.78 ± 1.92	0.003
	Week 10	4.16 ± 1.41	2.89 ± 2.01	0.001
Dyspareunia	Baseline	2.70 ± 2.13	2.05 ± 1.64	0.095
	Week 4	3.97 ± 1.63	2.87 ± 1.85	0.005
	Week 8	4.16 ± 1.67	2.77 ± 1.96	0.001
	Week 10	4.11 ± 1.75	2.55 ± 2.19	0.001
Total	Baseline	14.38 ± 9.41	10.89 ± 8.49	0.124
	Week 4	20.63 ± 6.72	14.54 ± 8.60	0.005
	Week 8	22.17 ± 6.28	14.37 ± 9.82	0.001
	Week 10	21.63 ± 7.02	13.93 ± 10.31	<0.001

The data are presented as mean (standard deviation). For comparison of the groups, an independent t-test was used.